U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Protein
Created
by admin
on Sat Dec 16 12:11:29 GMT 2023
Edited
by admin
on Sat Dec 16 12:11:29 GMT 2023
Protein Sub Type
Sequence Type COMPLETE
Record UNII
AL17N8ZSWL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA
Common Name English
PPAR-GAMMA
Common Name English
PPARG
Common Name English
NUCLEAR RECEPTOR SUBFAMILY 1 GROUP C MEMBER 3
Common Name English
Code System Code Type Description
FDA UNII
AL17N8ZSWL
Created by admin on Sat Dec 16 12:11:32 GMT 2023 , Edited by admin on Sat Dec 16 12:11:32 GMT 2023
PRIMARY
UNIPROT
P37231
Created by admin on Sat Dec 16 12:11:32 GMT 2023 , Edited by admin on Sat Dec 16 12:11:32 GMT 2023
PRIMARY
WIKIPEDIA
PEROXISOME_PROLIFERATOR-ACTIVATED_RECEPTOR_GAMMA
Created by admin on Sat Dec 16 12:11:32 GMT 2023 , Edited by admin on Sat Dec 16 12:11:32 GMT 2023
PRIMARY
Glycosylation Type HUMAN
Glycosylation Link Type Site
O 1_84
Related Record Type Details
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
Binding Assay
IC50
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
INHIBITOR -> TARGET
Binding Assay
IC50
INHIBITOR -> TARGET
PARTIAL AGONIST->TARGET
In a cell-based reporter assay designed to detect full agonist activity, INT131 activates PPARγ with an efficacy of only about 10% of that of rosiglitazone.
BINDING
Ki
ACTIVATOR -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
WEAK AGONIST->TARGET
PARTIAL AGONIST->TARGET
AGONIST -> TARGET
ACTIVATOR -> TARGET
AGONIST -> TARGET
Tesaglitazar is a novel dual-acting peroxisome proliferator-activated receptor alpha and gamma agonist.
AGONIST -> TARGET
INHIBITOR -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
Ki=4.7 micromolar (Supplementary Fig. S5; http://clincancerres.aacrjournals.org/content/22/10/2508.figures-only)
IN-VITRO
IC50
INHIBITOR -> TARGET
AGONIST -> TARGET
sarogli tazar has a predominant affinity for the PPAR-α isoform, and an intermediate affinity for PPAR-γ
AGONIST -> TARGET
INHIBITOR -> TARGET
IC50
AGONIST -> TARGET
PARTIAL AGONIST->TARGET
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
Binding Assay
IC50
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
AGONIST -> TARGET
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT CHEMICAL